Wolfe Laboratories Expands its Senior Management Operational Team

Woburn, Mass. — May 17, 2016 — Wolfe Laboratories, Inc. today announced the expansion of its senior management team through the addition of Paul Oakley, who has joined as Senior Vice President and General Counsel. In this role, Mr. Oakley will be responsible for the company’s corporate and financial strategies and general operations. Mr. Oakley brings more than 20 years of experience as an executive and entrepreneur, building and managing high-growth, mission-oriented teams and organizations, as well as an external general counsel for a vast portfolio of emerging growth companies.

“Paul is a tremendous addition to our team. He brings uniquely integrated business, legal and strategic perspectives which will be invaluable in helping us navigate during this time of rapid growth,” said Janet Wolfe, President and CEO of Wolfe Laboratories and to whom Mr. Oakley will be reporting. “With the tremendous demand for integrated pharmaceutical development services, Paul is arriving at the perfect time to lead and optimize our business and operational strategies, ensuring we capitalize on the considerable opportunities before us.”

Prior to joining Wolfe, Mr. Oakley served as Chief Administrative Officer for Truelight, LLC, an innovative energy firm engaged in short-term trading in the wholesale electricity markets through its proprietary hedge fund, TrueLight Energy Fund, L.P. He was also responsible for delivering analytics and business intelligence solutions to the $78B-and-growing competitive retail electricity supply sector and to the multi-billion-dollar clean energy development community through its subsidiary, TrueLight Energy, LLC.

“I am delighted to join Wolfe, particularly at this important moment in the company’s development, which is advancing rapidly,” said Mr. Oakley. “Wolfe’s integrated pharmaceutical development services for small molecules, biologics and complex molecules, and its key location in Boston’s thriving biopharma ecosystem, provides significant opportunities for value creation over the coming months and years. The strength of Wolfe’s integrated services presents multiple avenues for achieving growth, and I look forward to leading that process.”

Previously, Mr. Oakley was a corporate finance and transactional partner at Sullivan & Worcester, one of the leading private law firms headquartered in Boston, MA. He advised management teams and corporate boards on a wide variety of matters, such as financial strategies and legal precedence, in a range of industries including software, telecommunications, information technology, life sciences, medical devices, energy and clean tech.  He began his legal career as an associate at firms in New York City and Washington, D.C. Prior to practicing law, Mr. Oakley held communications positions in advertising and public relations, and also as a reporter.

Mr. Oakley received his Bachelor’s degrees in English and Journalism from the University of Missouri-Columbia and a Master’s degree in International Politics from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Mr. Oakley received his Juris Doctor, graduating cum laude, from the College of Law at Syracuse University, where he was on the editorial board of the Syracuse Law Review

About Wolfe Laboratories

Wolfe Laboratories, Inc. is a premier contract research organization that provides integrated drug development solutions to the biopharmaceutical industry. Wolfe Laboratories is an essential element of the drug development ecosystem, recognized by global and virtual biopharmaceutical companies as a science-driven organization whose mission is to provide outstanding discovery and development services tailored to its clients’ needs for rational formulation development. Wolfe Laboratories integrates the critical path components of early development to ensure that programs advance while meeting rigorous scientific demands with flexibility to address dynamic challenges and aggressive timelines. Wolfe Laboratories’ vision is to improve human health, and we continue to strive towards that goal by embracing our core values of integrity, excellence and teamwork. The company has a high percentage of repeat clients, which is a testament to its long-term commitment of continual investment in its capabilities to meet biopharma's growing demand for high quality, integrated early development services. Founded in 1999, the company is located in Woburn, Massachusetts.

For more information, please visit www.wolfelabs.com


Media Contact:

Karen Sharma
MacDougall Biomedical Communications